Anti-Interleukin Mirikizumab14,15 SERENITY (phase 2), VIVID (phase 3, ongoing) Humanized IgG4 monoclonal antibody with selective binding to the p19 subunit of IL-23; IV and SQ • Efficacy (clinical): Clinical improvements (CDAI and PRO-2) were observed in the mirikizumab 600 mg (35...
Mirikizumab is a humanized immunoglobulin G4 monoclonal antibody that binds to the p19 subunit of interleukin (IL)-23 (1). Given the selectivity to IL-23 without binding IL-12, mirikizumab is the first agent in this class of therapies to be authorized by the European Medicines Agency ...
Mirikizumab is an antibody that works against a portion of IL-23 and thus?suppresses inflammation in the colon. Mirikizumab was shown to be effective in alleviating symptoms and resolving inflammation of the colon in patients with UC. The drug was safe and well tolerated by patients. Miri...
(AEs) and serious AEs among patients treated with mirikizumab was consistent with that of the previous Phase 2 mirikizumab study in UC and studies with the anti-IL-23p19 antibody class. The most common AEs ...
ULCERATIVE colitisCLINICAL drug trialsPLACEBOSBackground/Aims: Mirikizumab is a p19-directed anti-interleukin-23 antibody with potential efficacy against ulcerative colitis (UC). We evaluated the efficacy and safety of mirikizumab in a Japanese subpopulation with moderately to severely ac...
Mirikizumab: First ApprovalJAPANTHERAPEUTIC use of monoclonal antibodiesULCERATIVE colitisCROHN'S diseaseDRUG approvalINTERLEUKINSMONOCLONAL antibodiesDRUG developmentCHEMICAL inhibitorsMirikizumab (Omvoh), a humanized IgG4 anti-human IL-23p19 monoclonal antibody, is being developed by Eli Lilly and ...